GEN Exclusives

More »


More »
Feb 1, 2010 (Vol. 30, No. 3)

Cryopreserved PBMCs and Cell-Based Assays

Preserving Fundamental Characteristics for Immune Monitoring and Drug Development

  • Conclusions

    The use of standardized conditions for cryopreservation using specific media and well-monitored storage conditions in conjunction with the use of optimized thawing protocols leads to optimal preservation of fundamental characteristics of PBMCs. This enables adherence to critical requirements important in the design and execution of large-scale longitudinal or cross-sectional studies throughout drug development.

    In addition, the availability of well-characterized cryopreserved PBMCs enables ex vivo testing of leads under varying conditions. The large batch sizes contribute to consistency and reproducibility of results and provide sufficient cells that can be used as controls pertinent to a particular study. Cyropreserved PBMCs and companion assays such as ELISpot and other cell-based assays comprise a unique toolbox to facilitate progress in preclinical and clinical stages of drug development. 

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »